Cambridge biotech Sarepta asks US to allow use of experimental Ebola drug – The Boston Globe
1
A Cambridge-based biotech company that has developed an experimental treatment for the Ebola virus is urging federal officials to consider allowing the unproven medication to be used on patients who have been infected in Africa’s deadly outbreak and brought to the United States for treatment.
Sarepta Therapeutics says it has enough doses of its injectible drug — AVI-7537 — to treat about two dozen patients within a week and could ramp up a supply for another 100 patients within a few months…
One thought on “Cambridge biotech Sarepta asks US to allow use of experimental Ebola drug – The Boston Globe”
Leave a Reply
You must be logged in to post a comment.
And how will they come up with an appropriate price for a lifesaving drug such as this?